plerixafor has been researched along with Dysmyelopoietic Syndromes in 4 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 3 (75.00) | 24.3611 |
| 2020's | 1 (25.00) | 2.80 |
| Authors | Studies |
|---|---|
| Abboud, C; Cashen, AF; Christ, S; DiPersio, JF; Eades, WC; Fletcher, T; Gehrs, L; Ghobadi, A; Huselton, E; Kulkarni, S; McFarland, K; Rettig, MP; Ritchey, J; Romee, R; Schroeder, MA; Stockerl-Goldstein, K; Trinkaus, K; Uy, GL; Vij, R; Westervelt, P | 1 |
| Absalon, MJ; Ahmed, A; August, K; Baker, SD; Boklan, J; Brown, PA; Cooper, TM; Gore, L; Li, L; Macy, ME; Magoon, D; Narendran, A; Pollard, J; Sison, EAR; Trippett, T | 1 |
| Kayamori, K; Kuwabara, C; Shimizu, R; Suzuki, Y; Tanaka, H | 1 |
| Abidi, MH; Abrams, J; Al-Kadhimi, Z; Ayash, L; Deol, A; Lum, LG; Masood, A; Ratanatharathorn, V; Uberti, JP | 1 |
3 trial(s) available for plerixafor and Dysmyelopoietic Syndromes
| Article | Year |
|---|---|
A phase I trial evaluating the effects of plerixafor, G-CSF, and azacitidine for the treatment of myelodysplastic syndromes.
Topics: Azacitidine; Benzylamines; Cyclams; Granulocyte Colony-Stimulating Factor; Hematopoietic Stem Cell Mobilization; Heterocyclic Compounds; Humans; Myelodysplastic Syndromes | 2021 |
A phase 1 study of the CXCR4 antagonist plerixafor in combination with high-dose cytarabine and etoposide in children with relapsed or refractory acute leukemias or myelodysplastic syndrome: A Pediatric Oncology Experimental Therapeutics Investigators' Co
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Benzylamines; Child; Child, Preschool; Cyclams; Cytarabine; Etoposide; Female; Heterocyclic Compounds; Humans; Leukemia, Myeloid, Acute; Male; Myelodysplastic Syndromes; Neoplasm Recurrence, Local; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Receptors, CXCR4; Treatment Outcome; Young Adult | 2017 |
Long-term follow up of patients proceeding to transplant using plerixafor mobilized stem cells and incidence of secondary myelodysplastic syndrome/AML.
Topics: Adult; Aged; Benzylamines; Compassionate Use Trials; Cyclams; Female; Follow-Up Studies; Hematopoietic Stem Cell Mobilization; Hematopoietic Stem Cell Transplantation; Hematopoietic Stem Cells; Heterocyclic Compounds; Humans; Incidence; Leukemia, Myeloid, Acute; Male; Middle Aged; Myelodysplastic Syndromes; Neoplasms, Second Primary; Survival Analysis; Treatment Outcome; Young Adult | 2013 |
1 other study(ies) available for plerixafor and Dysmyelopoietic Syndromes
| Article | Year |
|---|---|
Therapy-related Myelodysplastic Syndrome after Autologous Stem Cell Transplantation Using Plerixafor for Mobilized Stem Cells in a Patient with Multiple Myeloma.
Topics: Autografts; Benzylamines; Cyclams; Female; Hematopoietic Stem Cell Mobilization; Heterocyclic Compounds; Humans; Middle Aged; Multiple Myeloma; Myelodysplastic Syndromes; Stem Cell Transplantation | 2018 |